AstraZeneca study shows cardiovascular benefits of Farxiga

AstraZeneca has announced the findings of a real-world evidence study showing the cardiovascular benefits associated with its drug Farxiga.

The company has carried out a new analysis of the landmark CVD-REAL study, the first large real-world evidence study of its kind evaluating cardiovascular risks among type 2 diabetes patients receiving treatment with SGLT-2 inhibitors such as Farxiga.

It was shown that treatment with an SGLT-2 inhibitor therapy was associated with a 49 percent lower risk of all-cause death, a 36 percent lower rate of hospitalisation for heart failure, a 19 percent reduction in heart attacks and a 32 percent lower chance of stroke compared to other type 2 diabetes medicines.

This latest analysis was the first to include heart attack and stroke endpoints, as well as a longer follow-up period than previous studies and data from six additional countries across Asia Pacific, the Middle East and North America.

Elisabeth Bjork, vice-president and head of cardiovascular and metabolic diseases for AstraZeneca's global medicines development business, said: "With the majority of patients in this latest analysis being treated with Farxiga, these results suggest there is a strong association of cardiovascular benefits with the use of Farxiga across diverse patient ethnic and racial demographics."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.